Table 1. Number and percentage of subjects with a ≥4-fold increase in OprF/I-specific IgG antibody geometric mean titer from day 0 (first vaccination) to day 14 (7 d after second vaccination) (per-protocol-population).

Treatment group		Number of subjects with ratio day 14/day 0 ≥ 4	% (95% CI)a
IC43 100 µg	(n = 30)	29	96.7% (83.3%, 99.4%)
IC43 100 µg w/o	(n = 30)	29	96.7% (83.3%, 99.4%)
IC43 200 µg	(n = 30)	29	96.7% (83.3%, 99.4%)
IC43 50 µg	(n = 11)	10	90.9% (62.3%, 98.4%)
Placebo	(n = 32)	0	0.0% (0.0%, 10.7%)

^a 95% Confidence intervals were calculated according to the Wilson method recommended by Altman.¹⁷ CI, confidence interval; IgG, immunoglobulin G; OprF/I, outer membrane protein OprF/I hybrid vaccine; w/o, without adjuvant.